{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:07:29Z","timestamp":1794276449065,"version":"4.9.0"},"reference-count":58,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Health and Medical Research Council of Australia","award":["APP1053206"],"award-info":[{"award-number":["APP1053206"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP1107178"],"award-info":[{"award-number":["APP1107178"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP1108422"],"award-info":[{"award-number":["APP1108422"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP2001692"],"award-info":[{"award-number":["APP2001692"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP2008983"],"award-info":[{"award-number":["APP2008983"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2023,4,24]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>To provide clarity for research studies and clinical care, a set of positive criteria for adults and children with metabolic (dysfunction) associated fatty liver disease (MAFLD) was recently published and has subsequently been widely endorsed. The development and subsequent validation of the criteria for MAFLD has created a positive momentum for change. During the course of the ongoing discussion on the redefinition, some concerns have surfaced that we thought needs clarification. In this review, we provide a perspective on MAFLD and bringing clarity to some of the key aspects that have been recently raised.<\/jats:p>","DOI":"10.1136\/egastro-2023-100019","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:35:13Z","timestamp":1694439313000},"page":"e100019","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Two years on, a perspective on MAFLD"],"prefix":"10.1136","volume":"1","author":[{"given":"Mohammed","family":"Eslam","sequence":"first","affiliation":[{"name":"Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[{"name":"Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"2025081719082184000_1.2.e100019.1","doi-asserted-by":"crossref","first-page":"101291","DOI":"10.1016\/j.shpsc.2020.101291","article-title":"A typology of clinical conditions","volume":"83","author":"Tresker","year":"2020","journal-title":"Stud Hist Philos Biol Biomed Sci"},{"key":"2025081719082184000_1.2.e100019.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"2025081719082184000_1.2.e100019.3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","article-title":"Metabolic dysfunction-associated fatty liver disease: a year in review","volume":"38","author":"Alharthi","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"2025081719082184000_1.2.e100019.4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (Dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719082184000_1.2.e100019.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"2025081719082184000_1.2.e100019.6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"M\u00e9ndez-S\u00e1nchez","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719082184000_1.2.e100019.7","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2021.01.015","article-title":"The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD","volume":"74","author":"Spearman","year":"2021","journal-title":"J Hepatol"},{"key":"2025081719082184000_1.2.e100019.8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","article-title":"The Latin American Association for the study of the liver (ALEH) position statement on the redefinition of fatty liver disease","volume":"6","author":"Mendez-Sanchez","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719082184000_1.2.e100019.9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2021.11.003","article-title":"\u201cReply to: correspondence on \u201cthe Chinese society of Hepatology position statement on the redefinition of fatty liver disease\u201d\u201d","volume":"76","author":"Xu","year":"2022","journal-title":"J Hepatol"},{"key":"2025081719082184000_1.2.e100019.10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/RMHP.S285880","article-title":"MAFLD criteria guide the subtyping of patients with fatty liver disease","volume":"14","author":"Huang","year":"2021","journal-title":"Risk Manag Healthc Policy"},{"key":"2025081719082184000_1.2.e100019.11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","article-title":"Metabolic (Dysfunction)-Associated fatty liver disease in individuals of normal weight","volume":"19","author":"Eslam","year":"2022","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"2025081719082184000_1.2.e100019.12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"2025081719082184000_1.2.e100019.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.040"},{"key":"2025081719082184000_1.2.e100019.14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/j.gastro.2019.05.064","article-title":"Toward more accurate nomenclature for fatty liver diseases","volume":"157","author":"Eslam","year":"2019","journal-title":"Gastroenterology"},{"key":"2025081719082184000_1.2.e100019.15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.32642","article-title":"Metabolic dysfunction\u2010associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality","volume":"77","author":"van Kleef","year":"2023","journal-title":"Hepatology"},{"key":"2025081719082184000_1.2.e100019.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01878-2","article-title":"Association between patterns of alcohol consumption (beverage type, frequency and consumption with food) and risk of adverse health outcomes: a prospective cohort study","volume":"19","author":"Jani","year":"2021","journal-title":"BMC Med"},{"key":"2025081719082184000_1.2.e100019.17","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2468-2667(18)30230-5","article-title":"Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK million women study","volume":"4","author":"Simpson","year":"2019","journal-title":"Lancet Public Health"},{"key":"2025081719082184000_1.2.e100019.18","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cmet.2019.11.006","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab"},{"key":"2025081719082184000_1.2.e100019.19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22942","article-title":"Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US","volume":"3","author":"Pollard","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025081719082184000_1.2.e100019.20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2014.12.005","article-title":"Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study","volume":"62","author":"Askgaard","year":"2015","journal-title":"J Hepatol"},{"key":"2025081719082184000_1.2.e100019.21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1751-2980.13071","article-title":"The importance and impact of recognizing metabolic Dysfunction\u2010Associated fatty liver disease in patients with chronic hepatitis C","volume":"23","author":"Al-Omary","year":"2022","journal-title":"J Dig Dis"},{"key":"2025081719082184000_1.2.e100019.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07640.x"},{"key":"2025081719082184000_1.2.e100019.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01482.x"},{"key":"2025081719082184000_1.2.e100019.24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz509","article-title":"Presumed nonalcoholic fatty liver disease among medicare beneficiaries with HIV, 2006-2016","volume":"7","author":"Paik","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025081719082184000_1.2.e100019.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e3502","article-title":"Preventing overdiagnosis: how to stop harming the healthy","volume":"344","author":"Moynihan","year":"2012","journal-title":"BMJ"},{"key":"2025081719082184000_1.2.e100019.26","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.47"},{"key":"2025081719082184000_1.2.e100019.27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/hepr.13738","article-title":"Atherosclerotic cardiovascular disease in non\u2010metabolic nonalcoholic fatty liver disease","volume":"52","author":"Tsutsumi","year":"2022","journal-title":"Hepatol Res"},{"key":"2025081719082184000_1.2.e100019.28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025081719082184000_1.2.e100019.29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12072-015-9689-y","article-title":"Genetic and epigenetic mechanisms of NASH","volume":"10","author":"Eslam","year":"2016","journal-title":"Hepatol Int"},{"key":"2025081719082184000_1.2.e100019.30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3977"},{"key":"2025081719082184000_1.2.e100019.31","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jhep.2017.11.038","article-title":"The PNPLA3 SNP Rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort","volume":"68","author":"Meffert","year":"2018","journal-title":"J Hepatol"},{"key":"2025081719082184000_1.2.e100019.32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06540-3","article-title":"Phenome-wide Association studies across large population cohorts support drug target validation","volume":"9","author":"Diogo","year":"2018","journal-title":"Nat Commun"},{"key":"2025081719082184000_1.2.e100019.33","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jhep.2020.10.019","article-title":"Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling","volume":"74","author":"Xia","year":"2021","journal-title":"J Hepatol"},{"key":"2025081719082184000_1.2.e100019.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2020.03.003"},{"key":"2025081719082184000_1.2.e100019.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500398102"},{"key":"2025081719082184000_1.2.e100019.36","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3285"},{"key":"2025081719082184000_1.2.e100019.37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28475"},{"key":"2025081719082184000_1.2.e100019.38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12757","article-title":"MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C","volume":"7","author":"Thabet","year":"2016","journal-title":"Nat Commun"},{"key":"2025081719082184000_1.2.e100019.39","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/hep.29064","article-title":"The membrane\u2010bound O\u2010acyltransferase domain\u2010containing 7 variant Rs641738 increases inflammation and fibrosis in chronic hepatitis B","volume":"65","author":"Thabet","year":"2017","journal-title":"Hepatology"},{"key":"2025081719082184000_1.2.e100019.40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/ajg.2017.28","article-title":"Caution in using non-invasive scoring systems in NAFLD beyond highly selected study populations","volume":"112","author":"Armstrong","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2025081719082184000_1.2.e100019.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"2025081719082184000_1.2.e100019.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.037"},{"key":"2025081719082184000_1.2.e100019.43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apt.16513","article-title":"PRO\u2010C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol\u2010related liver disease","volume":"54","author":"Madsen","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025081719082184000_1.2.e100019.44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047786","article-title":"Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests","volume":"11","author":"Rhodes","year":"2021","journal-title":"BMJ Open"},{"key":"2025081719082184000_1.2.e100019.45","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","article-title":"A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients","volume":"116","author":"Eslam","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2025081719082184000_1.2.e100019.46","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jgh.15799","article-title":"Validation of five hepatic steatosis algorithms in metabolic\u2010associated fatty liver disease: a population based study","volume":"37","author":"Liu","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2025081719082184000_1.2.e100019.47","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"The Lancet"},{"key":"2025081719082184000_1.2.e100019.48","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"The Lancet"},{"key":"2025081719082184000_1.2.e100019.49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","article-title":"Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719082184000_1.2.e100019.50","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cgh.2022.05.046","article-title":"The prevalence and determinants of NAFLD and MAFLD and their severity in the VA primary care setting","volume":"21","author":"Thrift","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025081719082184000_1.2.e100019.51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/liv.15139","article-title":"Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta\u2010analysis: focusing on the Non\u2010Overlap groups","volume":"42","author":"Ayada","year":"2022","journal-title":"Liver Int"},{"key":"2025081719082184000_1.2.e100019.52","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jhep.2021.01.022","article-title":"Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback","volume":"74","author":"Alem","year":"2021","journal-title":"J Hepatol"},{"key":"2025081719082184000_1.2.e100019.53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jhep.2021.04.021","article-title":"Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience","volume":"75","author":"M\u00e9ndez-S\u00e1nchez","year":"2021","journal-title":"J Hepatol"},{"key":"2025081719082184000_1.2.e100019.54","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.009"},{"key":"2025081719082184000_1.2.e100019.55","first-page":"S11","article-title":"Standards of medical care in diabetes--2010","volume":"33 Suppl 1","year":"2010","journal-title":"Diabetes Care"},{"key":"2025081719082184000_1.2.e100019.56","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S002"},{"key":"2025081719082184000_1.2.e100019.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.006"},{"key":"2025081719082184000_1.2.e100019.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2023-100019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T02:08:34Z","timestamp":1755482914000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2023-100019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,11]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/egastro-2023-100019"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2023-100019","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}